Experienced in Synovial Sarcoma

Dr. Ryan J. Mattison

Hematology Oncology | Hematology | Oncology
University Of Wisconsin Medical Foundation Inc
600 Highland Ave, 
Madison, WI 
Accepting New Patients
Offers Telehealth
Experienced in Synovial Sarcoma
University Of Wisconsin Medical Foundation Inc
600 Highland Ave, 
Madison, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ryan Mattison is a Hematologist Oncology specialist and a Hematologist in Madison, Wisconsin. Dr. Mattison is rated as an Experienced provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Mattison is currently accepting new patients.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WI
Hospital Affiliations
Stoughton Hospital
University Of Wi Hospitals & Clinics Authority
Uw Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Network Health
  • HMO
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION INC
600 Highland Ave, Madison, WI 53792

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase 1 Dose-Escalation and Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)
A Phase 1 Dose-Escalation and Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)
Enrollment Status: Completed
Publish Date: September 30, 2025
Intervention Type: Biological
Study Drug: WU-CART-007
Study Phase: Phase 1
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Suspended
Publish Date: September 22, 2025
Intervention Type: Biological
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging
Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Procedure, Other, Drug
Study Drugs: Cytarabine, Fluorothymidine F-18
Study Phase: Phase 2
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab
Study Phase: Phase 2/Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: Inotuzumab ozogamicin, Prednisone, Daunorubicin, Vincristine, Cytarabine, Methotrexate, Pegaspargase
Study Phase: Phase 1
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 11 Less Clinical Trials
Similar Doctors
Advanced in Synovial Sarcoma
Dr. Howard H. Bailey
Oncology
Advanced in Synovial Sarcoma
Dr. Howard H. Bailey
Oncology
600 Highland Ave, 
Madison, WI 
 (0.1 miles away)
608-265-1700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Howard Bailey is an Oncologist in Madison, Wisconsin. Dr. Bailey is rated as a Distinguished provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Rhabdomyosarcoma Embryonal, Liposarcoma, and Prostatectomy. Dr. Bailey is currently accepting new patients.

Vaishalee P. Kenkre
Experienced in Synovial Sarcoma
Dr. Vaishalee P. Kenkre
Hematology Oncology | Hematology | Oncology
Experienced in Synovial Sarcoma
Dr. Vaishalee P. Kenkre
Hematology Oncology | Hematology | Oncology

University Of Wisconsin Medical Foundation Inc

600 Highland Ave, 
Madison, WI 
 (0.1 miles away)
608-263-6400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vaishalee Kenkre is a Hematologist Oncology specialist and a Hematologist in Madison, Wisconsin. Dr. Kenkre is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma (MZL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kenkre is currently accepting new patients.

Experienced in Synovial Sarcoma
Dr. Rubina D. Qamar
Hematology Oncology | Oncology | Hematology
Experienced in Synovial Sarcoma
Dr. Rubina D. Qamar
Hematology Oncology | Oncology | Hematology

University Of Wisconsin Medical Foundation Inc

1400 E Side Rd, 
Platteville, WI 
 (57.5 miles away)
608-348-2331
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rubina Qamar is a Hematologist Oncology specialist and an Oncologist in Platteville, Wisconsin. Dr. Qamar is rated as a Distinguished provider by MediFind in the treatment of Synovial Sarcoma. Her top areas of expertise are Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Tissue Biopsy. Dr. Qamar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mattison's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 12 Advanced Conditions
    View All 72 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile